Allogene Therapeutics, Inc. (ALLO) Institutional Ownership

Ownership Summary

Allogene Therapeutics, Inc. (NASDAQ:ALLO) showed up in the 13F filings of 166 institutional investors as of December 2025.

• Collectively, these holders controlled 71.8% of Allogene Therapeutics's outstanding shares in December 2025, down from 73.8% in September 2025.
• They increased total shares held in Allogene Therapeutics by 2.06% from last quarter, and the number of investors in ALLO decreased 3.49% annually.
• Of these 166 funds, 79 grew their exposure to Allogene Therapeutics, 46 cut back, and 41 maintained positions.
• Institutional investors collectively held 159.46Mn shares in Allogene Therapeutics as of December 2025, up by 3.21Mn shares quarter on quarter, and down 30.01Mn shares year over year.
• As of December 31, 2025, Pfizer Inc held the largest stake in Allogene Therapeutics with 22.03Mn shares, accounting for 9.92% of total shares outstanding.
• The most significant purchases of ALLO for the quarter ending December 2025 came from Kalehua Capital Management LLC (2.55Mn), Candriam S.C.A. (2.31Mn), Patient Square Capital LP (1.98Mn), Goldman Sachs Group Inc (1.09Mn), PRIMECAP MANAGEMENT CO/CA/ (1.06Mn).
• The biggest sellers of Allogene Therapeutics for the quarter ending December 2025 included UBS Group AG (2.18Mn), CITADEL ADVISORS LLC (1.86Mn), MILLENNIUM MANAGEMENT LLC (1.55Mn), DIMENSIONAL FUND ADVISORS LP (1.13Mn), Royal Bank Of Canada (1.05Mn).
• Allogene Therapeutics's 10 largest shareholders as of December 2025 include Pfizer Inc (22.03Mn), TPG GP A, LLC (18.72Mn), BlackRock, Inc. (17.68Mn), CITADEL ADVISORS LLC (12.11Mn), VANGUARD GROUP INC (9.25Mn), PRIMECAP MANAGEMENT CO/CA/ (8.14Mn), Patient Square Capital LP (4.96Mn), GEODE CAPITAL MANAGEMENT, LLC (3.93Mn), Frazier Life Sciences Management, L.P. (3.87Mn), Woodline Partners LP (3.5Mn) per Business Quant data.